openPR Logo
Press release

Aquigen Bio Strengthens Pharmaceutical Research with High-Purity Icatibant Impurity Standards

08-21-2025 05:07 PM CET | Chemicals & Materials

Press release from: Aquigen Bio Sciences

Aquigen Bio Strengthens Pharmaceutical Research with

Aquigen Bio, a trusted supplier of pharmaceutical reference standards, today announced the expansion of its Icatibant Impurity Standards portfolio, designed to support drug developers, analytical laboratories, and research organizations with reliable materials for impurity profiling and quality control.
Icatibant, a selective bradykinin B2 receptor antagonist, is widely used in the treatment of hereditary angioedema (HAE). Given its peptide-based structure, Icatibant is prone to the formation of impurities during synthesis and storage. Accurate detection and quantification of these impurities are critical to ensuring drug safety, efficacy, and regulatory compliance.
"With growing regulatory demands for impurity profiling, access to high-quality impurity standards has become essential," said a spokesperson for Aquigen Bio. "Our Icatibant impurity standards are manufactured with precision and purity, enabling pharmaceutical companies and laboratories to achieve accurate analytical results and meet global compliance requirements."
Aquigen Bio's Icatibant Impurity Portfolio Includes:
https://aquigenbio.com/product/icatibant-impurity-5/

https://aquigenbio.com/product/icatibant-impurity-6/

https://aquigenbio.com/product/icatibant-impurity-7/

https://aquigenbio.com/product/icatibant-impurity-9/

These standards are widely used for:
Method development and validation

Stability and degradation studies

Regulatory submission support

Batch-to-batch consistency in pharmaceutical manufacturing

Aquigen Bio's Icatibant Impurity Standards are developed to meet stringent global quality benchmarks, offering high purity, reliability, and reproducibility in results.

Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Visit: www.aquigenbio.com

Aquigen Bio is a leading provider of certified reference standards, impurity profiling compounds, and research chemicals to pharma, biotech, and academic institutions worldwide. With a dedication to excellence and a focus on regulatory readiness, Aquigen empowers scientists to innovate with confidence.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aquigen Bio Strengthens Pharmaceutical Research with High-Purity Icatibant Impurity Standards here

News-ID: 4154242 • Views:

More Releases from Aquigen Bio Sciences

Elevate Pharmaceutical R&D with Aquigen BioSciences' Precision‐Grade Flibanserin Impurity B: Custom Synthesis, Unmatched Purity, ANDA‐Ready Reference Standard to Drive Analytical Method Development and Regulatory Compliance
Elevate Pharmaceutical R&D with Aquigen BioSciences' Precision‐Grade Flibanser …
Flibanserin Impurity B is a reference standard used in pharmaceutical research and development. It is primarily applied during the analysis and validation of drug substances to identify, quantify, and control impurities that may be present in the final product. This impurity is associated with the parent compound, Flibanserin, a medication approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Aquigen BioSciences offers Flibanserin Impurity B as a
Estradiol Valerate EP Impurity A - Premium Reference Standard for Analytical Development, Quality Control, and Regulatory Compliance in Pharmaceutical Research
Estradiol Valerate EP Impurity A - Premium Reference Standard for Analytical Dev …
Estradiol Valerate EP Impurity A is a high-quality reference standard designed to meet the stringent requirements of pharmaceutical research, method validation, and quality control processes. Explore Estradiol Valerate EP Impurity A : https://aquigenbio.com/product/estradiol-valerate-ep-impurity-a/ Manufactured and characterized with precision, this impurity standard supports laboratories and manufacturers in achieving consistent, reliable, and reproducible results in critical analytical workflows. With its exceptional purity and accurate characterization, Estradiol Valerate EP Impurity A plays a vital role
High-Purity N-Nitroso Betahistine D3 for Precise Pharmaceutical Analysis | Deuterated Nitrosamine Impurity Standard for Method Development, Validation, Quality Control, and Regulatory Submissions in Betahistine Impurity Profiling and Research
High-Purity N-Nitroso Betahistine D3 for Precise Pharmaceutical Analysis | Deute …
Product Overview N-Nitroso Betahistine D3 is a premium deuterated nitrosamine impurity standard, specifically developed for precise analytical testing in pharmaceutical laboratories. This reference standard is widely used for analytical method development, validation, and quality control processes to meet stringent regulatory guidelines. With exceptional purity, complete documentation, and reliable traceability, it is ideal for research, development, and compliance applications. https://aquigenbio.com/product/n-nitroso-betahistine-d3/ Key Features and Benefits Deuterated Design for Precision: The incorporation of deuterium improves mass spectrometric
Elevating Analytical Precision with Harmine Impurity Standards
Elevating Analytical Precision with Harmine Impurity Standards
In the realm of pharmaceutical research, controlling the purity of compounds is pivotal. When evaluating psychoactive alkaloids such as harmine-a β-carboline alkaloid known for its reversible monoamine oxidase A inhibition and emerging therapeutic potential-accuracy is non-negotiable. This is where Aquigen Bio Sciences brings its edge: supplying high-grade impurity standards to underpin analytical consistency and regulatory compliance. Why Harmine Impurity Standards Matter https://aquigenbio.com/products/impurity-standards/harmine/ Harmine occurs naturally in Peganum harmala and Banisteriopsis caapi, and has

All 5 Releases


More Releases for Icatibant

06-10-2019 | Health & Medicine
Fact.MR
Peptide Based Hematological Disorders Therapeutics Market Set to Deliver Major R …
Peptide based haematological disorders therapeutics market is exhibiting robust growth. This is due to the fact that technology for the manufacturing of peptides is rapidly evolving, with manufacturers and suppliers exploring new methods for the manufacturing of peptides. This has a positive effect on the peptide therapeutics market and leads to the formation of longer and complex chain of peptides and reduced cost of production. In addition, due to the emergence
02-25-2019 | Health & Medicine
Fact.MR
Peptide Based Hematological Disorders Therapeutics Market Scenario Highlighting …
Peptide based haematological disorders therapeutics market is exhibiting robust growth. This is due to the fact that technology for the manufacturing of peptides is rapidly evolving, with manufacturers and suppliers exploring new methods for the manufacturing of peptides. This has a positive effect on the peptide therapeutics market and leads to the formation of longer and complex chain of peptides and reduced cost of production. In addition, due to the emergence
Peptide Based Hematological Disorders Therapeutics Market Shares, Strategies and …
This Fact.MR report on the global peptide based hematological disorders therapeutics market forecasts that the global peptide based hematological disorders therapeutics market will touch a value of nearly US$ 530 Mn in the year 2022 and grow at a robust CAGR during the assessment period. North America Market Set to Dominate the Global Peptide Based Hematological Disorders Therapeutics Market in Terms of Revenue The market in North America is set to dominate
12-10-2018 | Health & Medicine
Fact.MR
Peptide Based Hematological Disorders Therapeutics Market Expected to Secure Not …
Due to the advances in technology, the manufacturers and suppliers are encouraged to seek novel methods for peptide manufacturing, which is bound to improve the production of longer and complex chain of peptides and reduce the cost of production. Moreover, due to the automation of instruments, with improvements in the purification process and reduction in the total waste generated, are the driving factors triggering the growth of the global peptide
10-25-2018 | Health & Medicine
Fact.MR
Global Peptide Based Hematological Disorders Therapeutics Market Expectations & …
FactMR research firm has recently updated its massive report catalogue by adding a fresh study titled “Peptide Based Hematological Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022”. This business intelligence study encapsulates vital details about the market current as well as future status during the forecast period of 2017-2022 Readers can expect holistic and comprehensive analysis on the Peptide Based Hematological Disorders Therapeutics
Global Peptides and Heparin Market Research by Region - North America, Latin Ame …
A fresh study, covering “Peptide and Heparin Market Research Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2026” has been broadcasted to wide online repository of Fact MR, which presents deep focus on the healthcare market. This smart study contains precise data that offers a clear insight about market current scenario and future projections for the benefit of readers. Moreover, the study enclosed significant data which tends